Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. Show more
PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive...
All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway Vistagen (Nasdaq: VTGN), a late...
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 1.71232876712 | 2.92 | 3.1 | 2.81 | 150913 | 2.98282449 | CS |
4 | 0.38 | 14.6718146718 | 2.59 | 3.395 | 2.48 | 291894 | 3.02379186 | CS |
12 | -0.13 | -4.1935483871 | 3.1 | 3.395 | 2.22 | 284511 | 2.75918433 | CS |
26 | -0.93 | -23.8461538462 | 3.9 | 3.94 | 2.22 | 207284 | 2.92505973 | CS |
52 | -2.01 | -40.3614457831 | 4.98 | 5.74 | 2.22 | 201849 | 3.743481 | CS |
156 | -41.73 | -93.355704698 | 44.7 | 53.7 | 1.62 | 2991445 | 7.52439425 | CS |
260 | -20.13 | -87.1428571429 | 23.1 | 106.5 | 1.62 | 2502162 | 21.70439127 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales